Patent · US Active

Retinopathy treatment

US10792260B2 · kind B2 · utility

0Cited by
9References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 22, 2015
Grant dateOct 6, 2020
Priority date
Expiry dateApr 6, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K9/08
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.